Frontlight ResearchEarly access
CompletedNo phase
Study on Surgical Treatment Strategies for Moderate Ischemic Mitral Regurgitation
Key facts
- Who runs it
- China National Center for Cardiovascular Diseases
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 464 people enrolled
- Started
- 1 Aug 2023
- Ended
- 1 Apr 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- mitral valve repair
- Record updated
- 16 May 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Adult coronary artery disease patients complicated with moderate ischemic mitral regurgitation
- undergoing coronary artery bypass grafting with or without mitral valve repair
Who cannot take part
- patients undergoing concomitant aortic valve procedure
- patients complicated with primary mitral valve disease other than ischemic mitral regurgitation, such as rheumatic mitral regurgitation or mitral valve leaflet prolapse,
- patients under the age of 18 years,
- patients complicated with more than moderate ischemic mitral regurgitation or undergoing mitral valve replacement,
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aimed to compare the efficacy of isolated coronary artery bypass grafting and coronary artery bypass grafting + mitral valve repair in moderate ischemic mitral regurgitation patients through a cohort and explore the potential risk factors of the clinical outcomes.
The 2 groups in the trial
- coronary artery bypass grafting
Treatment: mitral valve repair
- coronary artery bypass grafting concomitant mitral valve repair
Treatment: mitral valve repair
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 May 2024